Medicine shortages
When a medicine is short, the national medicines agency usually says so, but each country publishes its notices in its own place, language and format, and many remove a notice once the problem ends. MPA collects the national notices across Europe, translates the reasons, matches each notice to the licence and pack it concerns and keeps ended notices for a year, so a supply problem can be read across markets and against the product's licences and prices.
What it holds
- The shortage notices published by national medicines agencies, pack by pack, with the product, active substance, strength, form and company.
- The type of notice: a temporary shortage, a discontinuation where the source says the product will not return, or a product listed as at risk or restricted from export.
- The dates as the source gives them: start, expected end, and when the source says the problem ended or stopped listing it.
- The reason as published, in the original wording and in English.
- Each notice matched to the national licence and pack it concerns, so it reads alongside the licences and prices for the same product.
- Ended notices kept for twelve months, so a product that has been short recently can be seen even after the national list drops it.
- Markets
- Most EU and EEA countries, with more added as each national list is brought in. The UK is not included.
- Not included
- Stock levels and wholesaler availability. The dataset holds what the national authorities publish, not what is in the supply chain.
Who uses it, and why
- Parallel traders and wholesalersTo see where a product is short or restricted from export before sourcing from that market, and where a shortage in a destination market creates demand.
- Procurement and buyersTo see which products they buy are short anywhere in Europe, how long it is expected to last, and whether the problem is spreading.
- Generics and biosimilar companiesTo see where a discontinuation or a long shortage leaves a gap that an authorised alternative could fill.
- Originators, brand and portfolio teamsTo see the supply notices on their own products and their competitors’ across Europe, as the authorities publish them.
- Consultancies and advisersThe supply record of a product or class across Europe, for a market study or a supply-risk review.
Questions it answers
Is this product short anywhere in Europe right now, and in which packs?
Is it a temporary shortage or a discontinuation?
When is the shortage expected to end, and has the source said it has?
Which countries list this product as at risk or restrict its export?
What reason did the authority give?
Has this product been short in the last year, even if the national list no longer shows it?
Which products in our range have a supply notice somewhere in Europe?
How it is searched
Assessing a product
- 1Search by substance, product or company.
- 2Read the notices country by country: the type, the dates, the reason in English and in the original, and the pack concerned.
- 3Narrow to current notices, or include those that ended in the last twelve months.
- 4If you also subscribe to the other datasets, read the licence holders and the published prices for the same product alongside.
Finding opportunities
- 1Work through a whole list of products in one go: your sourcing range, a tender list or a therapeutic class.
- 2Filter to export-restricted and at-risk products before planning a sourcing route.
- 3Find discontinuations and long-running shortages where an alternative supplier could be needed.
- 4Add prices and parallel import licences to see whether a supply gap can be met, and from where.
Expert support, included
A notice shows what an authority published, not what it means for your supply. Whether an export restriction covers your route, how a national list defines a shortage, and what has changed since the notice are questions we answer as part of every subscription.
What to read first
All resources- ExplainersMedicine shortage registers in EuropeEvery European country now publishes some record of medicines in short supply, and no two mean the same thing by 'shortage'. The EU-level sources, what the national registers and export-restriction lists record, and how traders, buyers and planners should read them.
- Regulatory changesExport restrictions on medicines, country by countryWhere a parallel exporter needs a licence, a notification or simply cannot ship: Greece's rolling three-month bans, Portugal's monthly suspension list, Belgium's prior authorisation, Poland's bi-monthly anti-export list, Italy's block list, Slovakia's new reform, Czechia's flag, and the countries where nothing changed in 2026. Revised each quarter.
- Regulatory changesThe UK's parallel-export and hoarding listWholesalers may not parallel-export or hoard a medicine on the Department of Health and Social Care's restricted list. In 2026 the list gained aspirin, rivastigmine, dinoprostone, cyclophosphamide, ramipril, raltitrexed, levothyroxine tablets, pentostatin, topotecan, cytarabine and mesna, and lost glucagon and terbutaline. How the list works, what is on it, and what an exporter must check before every shipment. Updated as the list moves.
- Regulatory changesThe EU package's shortage rulesThe part of the EU pharmaceutical package that arrives first. Once the reform is published, marketing authorisation holders will have to give twelve months' notice before permanently withdrawing a product from a Member State and six months before a suspension or any disruption expected to last more than two weeks, keep a shortage-prevention plan for every prescription medicine, and work to a Union list of critical medicines. These provisions apply about six months after entry into force, in 2027, well before the rest of the package in 2028.
- ExplainersUnlicensed medicinesA medicine with no marketing authorisation in a country can still reach a patient there, by one of several routes that each have their own rules, suppliers and prices. What the EU's named-patient and compassionate-use provisions allow, how the UK's specials and import notifications work, how the large member states run early access, and what the routes mean for traders, planners and buyers.
See MPA Search in action
A free online demonstration with our team, with time for your questions.